Research Analysts Offer Predictions for HRTX Q3 Earnings

Heron Therapeutics, Inc. (NASDAQ:HRTX) – Research analysts at Northland Securities boosted their Q3 2026 EPS estimates for shares of Heron Therapeutics in a research note issued on Thursday, March 26th. Northland Securities analyst C. Byrnes now anticipates that the biotechnology company will post earnings per share of $0.00 for the quarter, up from their prior estimate of ($0.01). The consensus estimate for Heron Therapeutics’ current full-year earnings is ($0.13) per share. Northland Securities also issued estimates for Heron Therapeutics’ Q4 2026 earnings at $0.01 EPS.

HRTX has been the subject of a number of other research reports. HC Wainwright reaffirmed a “buy” rating and issued a $6.00 price target on shares of Heron Therapeutics in a research report on Friday, January 9th. Zacks Research lowered Heron Therapeutics from a “hold” rating to a “strong sell” rating in a report on Thursday, February 26th. Finally, Weiss Ratings restated a “sell (e+)” rating on shares of Heron Therapeutics in a report on Thursday, January 22nd. Three research analysts have rated the stock with a Buy rating and two have assigned a Sell rating to the stock. According to data from MarketBeat, the stock presently has an average rating of “Hold” and an average price target of $4.50.

Heron Therapeutics Stock Performance

Shares of HRTX stock opened at $0.78 on Friday. The company has a quick ratio of 1.51, a current ratio of 2.48 and a debt-to-equity ratio of 10.59. The company has a market cap of $147.76 million, a P/E ratio of -6.03 and a beta of 1.26. Heron Therapeutics has a 52 week low of $0.75 and a 52 week high of $2.61. The business has a 50 day moving average of $1.13 and a two-hundred day moving average of $1.21.

Heron Therapeutics (NASDAQ:HRTX) last announced its quarterly earnings data on Thursday, February 26th. The biotechnology company reported ($0.02) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.03) by $0.01. The business had revenue of $40.59 million for the quarter, compared to the consensus estimate of $39.53 million.

Hedge Funds Weigh In On Heron Therapeutics

Several large investors have recently bought and sold shares of HRTX. PKS Advisory Services LLC acquired a new stake in Heron Therapeutics in the 3rd quarter worth $25,000. Advisory Services Network LLC raised its position in shares of Heron Therapeutics by 2,383.4% during the fourth quarter. Advisory Services Network LLC now owns 18,874 shares of the biotechnology company’s stock valued at $25,000 after buying an additional 18,114 shares during the last quarter. B. Riley Wealth Advisors Inc. bought a new stake in shares of Heron Therapeutics in the second quarter valued at about $26,000. Jones Financial Companies Lllp lifted its stake in shares of Heron Therapeutics by 5,541.2% in the third quarter. Jones Financial Companies Lllp now owns 24,088 shares of the biotechnology company’s stock valued at $29,000 after buying an additional 23,661 shares during the period. Finally, SG Americas Securities LLC grew its position in Heron Therapeutics by 39.1% during the fourth quarter. SG Americas Securities LLC now owns 24,377 shares of the biotechnology company’s stock worth $32,000 after buying an additional 6,858 shares in the last quarter. 80.01% of the stock is currently owned by institutional investors and hedge funds.

Heron Therapeutics Company Profile

Heron Therapeutics, Inc is a commercial-stage biotechnology company focused on developing and commercializing therapies in pain management and supportive care for patients undergoing medical and surgical procedures. The company’s research is dedicated to addressing unmet needs in oncology supportive care and post-operative pain management through innovative drug formulations designed to improve patient outcomes and reduce reliance on opioids.

Heron’s first approved therapy, SUSTOL (granisetron) extended-release injection, received U.S.